Oculopharyngeal Muscular Dystrophy
·MeSH: Muscular Dystrophy, Oculopharyngeal
Prevalence
200.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| bb-301 | Benitec Biopharma Inc. (BNTC) |
Frequently asked questions
How many drugs are in development for Oculopharyngeal Muscular Dystrophy?
BioSniper tracks 1 drug in development for Oculopharyngeal Muscular Dystrophy across 1 company.
How many clinical trials target Oculopharyngeal Muscular Dystrophy?
There are 1 clinical trial targeting Oculopharyngeal Muscular Dystrophy tracked by BioSniper.
What is the prevalence of Oculopharyngeal Muscular Dystrophy?
The estimated prevalence of Oculopharyngeal Muscular Dystrophy is approximately 200.0 per 100,000 population.
Deep-dive into Oculopharyngeal Muscular Dystrophy
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis